Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
59P - Identifying blood-based proteomic mediators of cancer-associated cachexia in non-small cell lung cancer in the TRACERx study
Presenter: Rachel Scott
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Unveiling the distinctive molecular, clinical, and prognostic features of infant acute myeloid leukemia: An analysis study of pediatric AML datasets from the Children's Oncology Group
Presenter: YU TAO
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Evaluating gene alterations associated with recurrence in oral cavity squamous cell carcinoma
Presenter: Amanda Reyes
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Multiplex immunofluorescence analysis of LRRC15 and the TME in early-stage lung adenocarcinoma
Presenter: Jessie Woon
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Molecular profile of triple-negative breast cancer tumours and their association with response to neoadjuvant treatment: A study using next generation sequencing
Presenter: Juan Ramón Berenguer-Marí
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Multi-institutional evaluation of interrater agreement of biomarker-drug pair rankings based on the ESMO scale for clinical actionability of molecular targets (ESCAT) and sources of discordance
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - ESR1 gene mutation in hormone receptor (HR)-positive metastatic breast cancers: An NGS-based exploratory study on Indian population
Presenter: Siddappa Shanthala
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Next generation sequencing in colorectal cancer: Association of BRAF, KRAS mutations with right sided cancers, mucinous disease, lymphovascular/perineural invasion and microsatellite instability
Presenter: Gurpreet Singh Ranger
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Increased expression of interleukin-17 receptor A (IL-17RA) promotes cancer stem-like properties, resistance to 5-fluorouracil, and the expression of ATP-binding cassette transporters in colorectal cancer cells
Presenter: Chih-Yung Yang
Session: Cocktail & Poster Display session
Resources:
Abstract